Danazol as first-line therapy for myelodysplastic syndromes

Conclusion Danazol as frontline therapy is an acceptable treatment option with low side effects for patients with MDS that cannot receive ASCT Teaser At present, no standard therapy is available for most patients with myelodysplastic syndromes. In this retrospective study, we analyse data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option due to its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Conclusions. ISV is widely used in hematological pts with IFI also in diseases other than acute myeloid leukemia and it is overall well tolerated. ORR to ISV is at least comparable with other antifungal agents. A rec/ref underlying hematological disease impacts both on OS and response to ISV, while having an IFI refractory to other antifungal agents including azoles does not seem to compromise the response to ISV, although this promising result should be confirmed in prospective studies and larger groups of patients.DisclosuresBusca: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Sp...
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III Source Type: research
This study analyzes patient and hospital characteristics of patients undergoing BMT, in addition the study describes resource utilization and outcomes of BMT among various hematological cancers.Methods: We performed a retrospective cohort analysis of the National Inpatient Sample 2014 Database (HCUP-NIS). Patients were included in the study if they had a procedure diagnosis of BMT and a medical diagnosis of acute or chronic leukemia (ALL, AML, CLL, CML), lymphoma (HL and NHL), MM, MDS or HLH. HSCT or BMT includes both Allogeneic and Autologous Stem Cell Transplant however we did not differentiate one from the other since B...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Poster III Source Type: research
Introduction:Allogeneic hematopoietic cell transplantation (alloHCT) has historically been reserved for younger, fit patients with hematologic malignancies. With the introduction of non-myeloablative conditioning regimens and improved supportive care, alloHCT has been increasingly offered to older adults.Objectives:To determine the association between functional status as measured by a cancer-specific comprehensive geriatric assessment (CGA) and post-transplant outcomes in an older alloHCT patient population.Methods:We conducted a prospective cohort study of patients aged 50 or older who underwent alloHCT at the University...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research
Background: Prior studies have demonstrated disparities in the utilization of stem cell transplant (SCT) based on age, race, and insurance type. Whether delays to SCT occur as a result of these disparities is not well established. We evaluated whether we observed similar trends in a large metropolitan SCT center with a large population of minority patients (pts).Methods: We identified pts at Karmanos Cancer Institute who had their initial SCT consultation from 2009 - 2016, and evaluated pts who received or did not receive SCT for the diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplast...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Costs and Disparities Source Type: research
Conclusion:We confirmed the positive impact viral reactivation after allo-HSCT on relapse incidence, which could be explained as a stimulation of both function and amplification of NK compartment. Our finding about viral co-reactivation that includes EBV with a higher risk of relapse should be further explored and carefully interpreted as this might come from EBV treatment by rituximab that impairs the immunological system by impacting the GVL effect and therefore leads to more relapse.DisclosuresMichallet: Octapharma: Membership on an entity's Board of Directors or advisory committees; Chugai: Consultancy; Novartis: Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster I Source Type: research
Background: Melphalan exposure as measured by area under the curve (AUC) has a 5-fold variability between pts, with higher AUCs associated with improved outcomes but increased toxicity (Shaw BBMT 2012). Evomela ® (propylene glycol free melphalan, PGF-MEL) is an intravenous formulation with improved stability and possibly less toxicity related to the solubilizing agent. We aimed to determine the pharmacokinetics (PK) and relationship between exposure and toxicities with this formulation in order to optimiz e dosing.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conclusion Danazol as first-line therapy is an acceptable treatment option with low side effects for patients with MDS who cannot receive ASCT. Micro-Abstract At present, no standard therapy is available for most patients with myelodysplastic syndrome. In this retrospective study, we analyze data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option because of its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a successful treatment modality for AML and MDS. Information on transplant outcomes among older patients is limited because of concern of adverse transplant-related mortality (TRM) and poor overall survival (OS).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion SDF-1/CXCR4 axis plays a crucial role in engraftment; however, more studies are warranted to assess their expression post-transplant. Evaluating the ligand (chemokine, SDF-1) or its receptor (CXCR4) may serve as potential surrogate markers for assessment of engraftment.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The Delphi method was useful for the classification and stratification of risk factors for IFI-FF in patients with onco-haematological diseases. Identifying key risk factors will contribute to a better management of IFI-FF in this group of patients at high or changing risk. PMID: 28198173 [PubMed - as supplied by publisher]
Source: Revista Espanola de Quimioterapia - Category: Drugs & Pharmacology Authors: Tags: Rev Esp Quimioter Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants